Mostrar el registro sencillo del documento
Esquemas de tratamiento de la enfermedad de Hansen con Poliquimioterapia: Una revisión sistémica
dc.rights.license | Atribución-NoComercial-SinDerivadas 4.0 Internacional |
dc.contributor.advisor | Cortés Luna, Jorge Alberto |
dc.contributor.advisor | Faizal Geagea, Michel |
dc.contributor.author | Lozada Bernal, Santiago |
dc.date.accessioned | 2021-01-28T17:47:02Z |
dc.date.available | 2021-01-28T17:47:02Z |
dc.date.issued | 2021-01-13 |
dc.identifier.uri | https://repositorio.unal.edu.co/handle/unal/78966 |
dc.description.abstract | AIM: To determine the therapeutic efficacy of the North American polychemotherapy scheme in comparison with the WHO polychemotherapy scheme for the treatment of leprosy. MATERIALS AND METHODS: A systematic review of the literature was conducted. They were found in PUBMED/MEDLINE: 3625 articles, EMBASE: 2701, COCHRANE/CENTRAL: 47, and ClinicalTrial.gov: 31. 834 duplicates were excluded and 5570 titles and abstracts were reviewed. Fifteen articles were selected for full-text reading. Twelve articles were excluded for comparisons not related to the NHDP scheme. After the full text assay, 3 studies were selected for inclusion in the review. RESULTS: The present systematic review did not identify any prospective or randomized studies comparing the NHDP versus WHO scheme in the long term, but identified two clinical trials comparing Rifampicin and Dapsone daily with Rifampicin monthly with Dapsone daily for the treatment of Multibacillary Leprosy (by the time of publication of these two studies, Clofazimine had not yet been introduced into the treatment schemes). The clinical trial with the largest number of patients concluded that treatment with Rifampicin daily may lead to a higher rate of treatment abandonment due to side effects and suggests that the scheme of Rifampicin with monthly administration is better because it has the same efficacy with respect to clinical improvement, bacillary index and morphological index. It is suggested to carry out clinical trials that address this research topic in order to clearly define which of the two treatment schemes is superior. |
dc.description.abstract | OBJETIVO: Determinar la eficacia terapéutica del esquema de poliquimioterapia Norteamericano en comparación con el esquema de poliquimioterapia de la OMS para el tratamiento de la Lepra. MATERIALES Y MÉTODOS: Se realizó una revisión sistemática de la literatura. Se encontraron en PUBMED/MEDLINE: 3625 artículos, EMBASE: 2701, COCHRANE/CENTRAL: 47 y ClinicalTrial.gov: 31. Se excluyeron 834 duplicados y se realizó la revisión de 5570 títulos y resúmenes. Fueron seleccionados para lectura a texto completo 15 artículos. Se excluyeron 12 artículos por realizar comparaciones no relacionadas con el esquema del NHDP. Luego de la revisión a texto completo fueron seleccionados 3 estudios para incluir en la revisión. RESULTADOS: La presente revisión sistemática no identificó estudios prospectivos o aleatorizados que compararan a largo plazo el esquema NHDP vs OMS, pero identificó dos ensayos clínicos que compararon Rifampicina y Dapsona diaria con Rifampicina dosis mensual con Dapsona dosis diaria para el tratamiento de la Lepra Multibacilar (para el tiempo de publicación de estos dos estudios no se había introducido aun la Clofazimina en el esquema de tratamiento). El ensayo clínico que contó con mayor número de pacientes concluyó que el tratamiento con Rifampicina diaria puede conducir a una mayor tasa de abandono de tratamiento por los efectos secundarios y sugiere que es mejor el esquema de Rifampicina con administración mensual por tener la misma eficacia con respecto a mejoría clínica, índice bacilar e índice morfológico. Se sugiere la realización de ensayos clínicos que aborden este tema de investigación para poder definir de forma clara cuál de los dos esquemas de tratamiento es superior. |
dc.description.sponsorship | Universidad Nacional de Colombia |
dc.format.extent | 49 |
dc.format.mimetype | application/pdf |
dc.language.iso | spa |
dc.rights | Derechos reservados - Universidad Nacional de Colombia |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.subject.ddc | 610 - Medicina y salud::616 - Enfermedades |
dc.title | Esquemas de tratamiento de la enfermedad de Hansen con Poliquimioterapia: Una revisión sistémica |
dc.type | Otro |
dc.rights.spa | Acceso abierto |
dc.type.driver | info:eu-repo/semantics/other |
dc.type.version | info:eu-repo/semantics/acceptedVersion |
dc.publisher.program | Bogotá - Medicina - Especialidad en Dermatología |
dc.description.degreelevel | Especialidades Médicas |
dc.publisher.branch | Universidad Nacional de Colombia - Sede Bogotá |
dc.relation.references | Geluk A. Correlates of immune exacerbations in leprosy. In Seminars in immunology. 2018; Vol. 39, pp. 111-118. Academic Press. |
dc.relation.references | Virmond M, Grzybowski A, Virmond L. Leprosy: A glossary. Clinics in dermatology. 2015; 33(1), 8-18. |
dc.relation.references | White C, Franco Paredes C. Leprosy in the 21st century. Clinical microbiology reviews. 2015; 28(1), 80-94. |
dc.relation.references | Alemu Belachew W, Naafs B. Position statement: LEPROSY: Diagnosis, treatment and follow‐up. Journal of the European Academy of Dermatology and Venereology. 2019; 33(7), 1205-1213. |
dc.relation.references | Scollard DM, Dacso MM, Abad-Venida ML. Tuberculosis and leprosy: classical granulomatous diseases in the twenty-first century. Dermatologic clinics. 2015; 33(3), 541-562. |
dc.relation.references | De las Aguas, JT. Estado Actual de la Terapéutica de la Lepra. Dermatología Cosmética, Médica y Quirúrgica. 2008; 6(2), 118-125. |
dc.relation.references | Deps PD, Collin SM, Robin S, Charlier P. Leprosy in skulls from the Paris Catacombs. Annals of Human Biology. 2020;1-6. |
dc.relation.references | Global leprosy situation, 2009. Wkly Epidemiol Rec 2009;84:333–340. |
dc.relation.references | Palit A, Kar HK. Prevention of transmission of leprosy: The current scenario. Indian journal of dermatology, venereology and leprology. |
dc.relation.references | W Cairns S Smith and Paul Saunderson. Leprosy. Clinical Evidence 2010;06:915. |
dc.relation.references | Desikan KV, Sreevatsa. Extended studies on the viability of Mycobacterium leprae outside the human body. Lepr Rev 1995;66:287–295. |
dc.relation.references | Lawn SD, Lockwood DNJ. Leprosy after starting antiretroviral treatment. BMJ 2007;334;217–218. |
dc.relation.references | Saunderson P, Gebre S, Desta K, et al.The pattern of leprosy-related neuropathy in the AMFES patients in Ethiopia: definitions, incidence, risk factors and outcome. Lepr Rev 2000;71:285–308. |
dc.relation.references | Rodrigues LC. Lockwood DN. Leprosy now: epidemiology, progress, challenges, and research gaps. The Lancet infectious diseases. 2011; 11(6), 464-470. |
dc.relation.references | Faizal M, Rincón G, Betancourth, M, Agudelo C. Guía de atención de lepra. Medicina y Laboratorio. 2011; 17, 359-388. |
dc.relation.references | Turner D, McGuinness S, Leder K. Leprosy: diagnosis and management in a developed setting. Internal medicine journal, 45(1), 2015: 109-112. |
dc.relation.references | Reibel F, Cambau E, Aubry A. (Update on the epidemiology, diagnosis, and treatment of leprosy. Medecine et maladies infectieuses. 2015; 45(9), 383-393. |
dc.relation.references | WHO [Resolution No. WHA 44] World health Assembly. In: Eliminationof leprosy: resolution of the 44th World Health Assembly. Geneva: WorldHealth Organization; 1991. |
dc.relation.references | Sarode G, Sarode S, Anand R, Patil S, Jafer M, Baeshen H, Awan KH. Epidemiological aspects of leprosy. Disease-a-Month, 2019: 100899. |
dc.relation.references | Assembly WH . Global leprosy update, 2013; reducing disease burden. Wkly Epidemiol Rec . 2014;89:389–400 . |
dc.relation.references | Richardus JH , Ignotti E , Smith WCS . Epidemiology of leprosy. The international textbook of leprosy. American Leprosy Missions . 2019 . |
dc.relation.references | Penna ML , Wand-Del-Rey-de-Oliveira ML , Penna G . Spatial distribution of leprosy in the Amazon region of Brazil. Emerg Infect Dis . 2009;15:650–652 . |
dc.relation.references | Fischer, M. Leprosy–an overview of clinical features, diagnosis, and treatment. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2017; 15(8), 801-827. |
dc.relation.references | Rivas AM, Gómez LM. Lepra. Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica. 2008; 16(3), 196-207. |
dc.relation.references | Shimoji Y, Ng V, Matsumura K, Fischetti V, Rambukkana A. A 21- kDa surface protein of Mycobacterium leprae binds peripheral nerve laminin-2 and mediates Schwann cell invasion. Proc Natl Acad Sci U S A. 1999;96:9857---62. |
dc.relation.references | Alter A, Grant A, Abel L, Alcaïs A, Schurr E. Leprosy as a genetic disease. Mamm Genome. 2011;22:19---31. |
dc.relation.references | Eichelmann K., González SG, Salas-Alanis, JC, Ocampo Candiani J. Leprosy. An update: definition, pathogenesis, classification, diagnosis, and treatment. Actas Dermo-Sifiliográficas (English Edition). 2013; 104(7), 554-563 |
dc.relation.references | Talhari C, Talhari S, Penna GO. Clinical aspects of leprosy. Clinics in dermatology. 2015; 33(1), 26-37. |
dc.relation.references | Lockwood DN, Sarno E, Smith WC. Classifying leprosy patients– searching for the perfect solution? Lepr Rev. 2007;78:317-320. |
dc.relation.references | Ridley DS, Jopling WH. A classification of leprosy for research purposes. Lepr Rev. 1962;33:119-128. |
dc.relation.references | Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966;34:255-273. |
dc.relation.references | Guerrero ET, Martínez FV, Diéguez CEA, Arrazola J, Arenas Guzmán, R. Lepra. Clasificación y cuadro clínico. Dermatología Revista Mexicana. 2012: 56(1), 47-54. |
dc.relation.references | Morfín-Maciel BM, Martínez MD. CJ. Evaluación inmunológica durante el tratamiento de un caso de lepra dimorfa lepromatosa. Revista Alergia México. 2016; 63(4), 413-419. |
dc.relation.references | Gamboa LA, Paredes M. Compromiso neurológico en la lepra. Univ med. 2003; 44 :217-223. |
dc.relation.references | Lewallen S, Courtright P. A overview of ocular leprosy after 2 decades of multidrug therapy. Int Ophthalmol Clin. 2007;47:87-101. |
dc.relation.references | Flores OR. La reacción leprosa una revisión. Dermatología Venezolana. 2000;38(3). |
dc.relation.references | Steinmann P, Reed SG, Mirza F, Hollingsworth TD, Richardus JH. Innovative tools and approaches to end the transmission of Mycobacterium leprae. The Lancet Infectious Diseases. 2017; 17(9), e298-e305. |
dc.relation.references | Colorado CL, Sánchez G, Guerrero MI, León CI. Confiabilidad y concordancia de dos escalas de lectura de baciloscopias para clasificación y seguimiento del tratamientocon múltiples medicamentos de los pacientes con lepra. Biomédica. 2011; 31(3), 403-409. |
dc.relation.references | Fajardo Ramírez GA. Tratamiento de la enfermedad de Hansen resistente a poliquimioterapia, revisión sistemática de la literatura. Departamento de Medicina Interna. Disponible en: https://repositorio.unal.edu.co/handle/unal/58931. |
dc.relation.references | López Antuñano FJ. Diagnóstico y tratamiento de la lepra. salud pública de méxico. 1998; 40, 66-75. |
dc.relation.references | Smith CS, Aerts A, Saunderson, P., Kawuma J, Kita E, Virmond M. Multidrug therapy for leprosy: a game changer on the path to elimination. The Lancet Infectious Diseases. 2017; 17(9), e293-e297. |
dc.relation.references | Kar HK, Gupta R. Treatment of leprosy. Clinics in dermatology. 2015; 33(1), 55-65. |
dc.relation.references | Fajardo, T. T., Villahermosa, L., Pardillo, F. E. F., Abalos, R. M., Burgos J, Cruz ED, Gelber RH. A comparative clinical trial in multibacillary leprosy with long-term relapse rates of four different multidrug regimens. The American journal of tropical medicine and hygiene, 2009; 81(2), 330-334. |
dc.relation.references | Cruz RCDS, Bührer-Sékula S, Penna GO. Ensayo clínico para la terapia multifármaco uniforme para pacientes con lepra en Brasil (U-MDT / CT-BR): enfoque de efectos adversos. Anais brasileiros de dermatologia, 2018; 93 (3), 377-384. |
dc.relation.references | Kroger A, Pannikar V, Htoon, MT. Ensayo abierto internacional de un régimen uniforme de tratamiento con múltiples fármacos durante seis meses para todos los tipos de pacientes con lepra: fundamento, diseño y resultados preliminares. Medicina tropical y salud internacional. 2008; 13 (5), 594-602. |
dc.relation.references | Prasad PVS, Babu A, Kaviarasan P. MDT-MB therapy in paucibacillary leprosy: A clinicopathological assessment. Indian Journal of Dermatology, Venereology, and Leprology. 2005;71(4), 242. |
dc.relation.references | Penna GO, Bührer-Sékula S, Kerr LRS. Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients. PLoS neglected tropical diseases. 2017;11(7), e0005725. |
dc.relation.references | Lazo-PorrasM, Prutsky GJ, Barrionuevo P. World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis. BMC infectious diseases, 2020; 20(1), 62. |
dc.relation.references | De Carsalade GY, Wallach D, Spindler E. Daily multidrug therapy for leprosy; results of a fourteen-year experience. International journal of leprosy and other mycobacterial diseases, 1997; 65(1), 37. |
dc.relation.references | Dasananjali K, Schreuder PA, Pirayavaraporn C. A study on the effectiveness and safety of the WHO/MDT regimen in the northeast of Thailand; a prospective study, 1984-1996. International journal of leprosy and other mycobacterial diseases, 1997; 65, 28-36. |
dc.relation.references | Christian M, Colston MJ, Ellard G. Response to treatment by multidrug regimens in the THELEP controlled clinical drug trials. Leprosy Review. 1996; 67(4), 260-279. |
dc.relation.references | Cellona RV, Balagon MV, Dela Cruz EC. Long-term Efficacy of 2 Year WHO Multiple Drug Therapy (MDT) in Multibacillary (MB) Leprosy Patients1. International journal of leprosy and other mycobacterial diseases, 2003; 71(4), 308. |
dc.relation.references | Dacso MM, Jacobson RR, Scollard, DM. Evaluation of multi-drug therapy for leprosy in the United States using daily rifampin. Southern medical journal. 2011; 104(10), 689-694. |
dc.relation.references | Opromolla DVA, Tonello CJS, McDougall AC A Controlled Trial to Compare the Therapeutic Effects of Dapsone in Combination with Daily or Once-Monthly Rifampin in Patients with Lepromatous Leprosy’. INTERNATIONAL. JOURNAL OF LEPROSY. 1981; 49(4). |
dc.relation.references | Yawalkar SJ, McDougall AC, Languillon J. Once-monthly rifampicin plus daily dapsone in initial treatment of lepromatous leprosy. The Lancet. 1982; 319(8283), 1199-1202. |
dc.relation.references | Maymone MB, Venkatesh S, Laughter M. Leprosy: Treatment and management of complications. Journal of the American Academy of Dermatology. 2020; 83(1), 17-30. |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |
dc.subject.proposal | Lepra |
dc.subject.proposal | Leprosy |
dc.subject.proposal | Enfermedad de Hansen |
dc.subject.proposal | Hansen's Disease |
dc.subject.proposal | Poliquimioterapia |
dc.subject.proposal | Polychemotherapy |
dc.subject.proposal | Quimioterapia combinada |
dc.type.coar | http://purl.org/coar/resource_type/c_1843 |
dc.type.coarversion | http://purl.org/coar/version/c_ab4af688f83e57aa |
dc.type.content | Text |
oaire.accessrights | http://purl.org/coar/access_right/c_abf2 |
Archivos en el documento
Este documento aparece en la(s) siguiente(s) colección(ones)
![Atribución-NoComercial-SinDerivadas 4.0 Internacional](/themes/Mirage2//images/creativecommons/cc-generic.png)